BIOMARKER ASSAY DEVELOPMENT

Fluofarma develops and performs custom biomarker assays based on high-content analysis technologies to support specific needs at preclinical and clinical stages. Biomarker assays are optimized for automated, multiplex and high-throughput biomarker quantification at the single-cell level across large collections of blood and tissue samples.

TISSUE BIOMARKER ASSAYS

Hundreds of tissue samples (archival tissues or clinical samples) can be assembled through tissue microarray approach, for large-scale biomarker analysis.

Hundreds of tissue samples (archival tissues or clinical samples) can be assembled through tissue microarray approach, for large-scale biomarker analysis.

Fluofarma develops specific strategies for biomarker quantification based on automated tissue imaging and high-content analysis. We select markers that are well-characterized in the pathological context of interest or predictive of drug efficacy or toxicity.

Eligible paraffin-embedded tissue samples can be:

Tissue samples Tissue sources Tissue origin
  • Tissue microarrays
  • Tissue sections
  • Commercial TMA
  • In-house custom-built TMA
  • Client tissue collection
  • Human archival tissues
  • Artificial 3D microtissues and xenografts (from in vivo experiments)
  • Animal tissues (from in vivo experiments)

For instance, the expression ratio of two biomarkers, their co-localization, or the activation of specific signaling pathways can be quantified at high-throughput in large tissue collections and correlated with clinical or genetic data.

> Tissue microarray approach, to process large experimental series at high-throughput

> Multiplexed imaging of IF -  (or IHC, when possible) stained tissue samples

> Automated biomarker analysis & quantification (biomarker expression levels and subcellular distribution, discrimination of cell subpopulations)

We develop modules and software application for image & signal processing, depending on both the biomarker and the tissue structure of interest.

>>> Learn more about our high-content histology services.

 

BLOOD BIOMARKER ASSAYS

Fluofarma develops and implements tailor-made strategies to quantify specific cellular biomarkers/surrogate biomarkers in blood samples.

In the context of in vivo studies or clinical trials, blood biomarker assays can serve, for instance, to assess drug efficacy, to perform pharmacokinetic studies, or to stratify patients in trials.

> Immunostaining and multiplexing of cell surface and intracellular markers  such as phosphoproteins and other key actors of signaling pathways

> Multiplexed detection by 3-laser flow cytometry

> Fast turnaround: automated analysis in 96-/384-well plates

Fluofarma develops methods enabling the multiplexed detection of a large panel of biomarkers in blood samples, including intracellular markers such as kinase activation, detected by high-throughput flow cytometry.